3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Vomiting
1
Uterine Cervical Neoplasms
1
Postoperative Nausea and Vomiting
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Interventions
pembrolizumab
42
Paclitaxel
26
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Nivolumab
16
fludarabine
15
Docetaxel
13
aldesleukin
12
Gemcitabine
11
Fulvestrant
11
veliparib
9
Bevacizumab
9
sargramostim
8
palbociclib
8
durvalumab
8
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
liposomal doxorubicin
7
atezolizumab
7
Surveys and Questionnaires
7
Ipilimumab
7
Blood Specimen Collection
7
niraparib
6
avelumab
6
Taxes
6
Specimen Handling
6
Interleukin-2
6
Fluorouracil
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Diphenhydramine
×
Breast
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled